Incyte | INCY - Trade Creditors


Incyte reported $1.39B in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agenus USD 58.98M 12.1M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Exelixis USD 39.06M 14.91M Jun/2026
Gilead Sciences USD 645M 70M Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
MacroGenics USD 3.44M 845K Jun/2026
Merck USD 3.83B 36M Jun/2026
Moderna USD 167M 6M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.26B 64M Jun/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026